eligibility_summary
Adults ≥18 with HCC: BCLC C or B not for locoregional therapy, Child-Pugh A, ECOG 0–1, ≥1 prior systemic therapy, RECIST-measurable, adequate organ function, AEs resolved, controlled HBV/HCV, treated varices, contraception. Exclude: variant histology, transplant, Vp4 PVTT, encephalopathy/ascites, liver EBRT/radioembolization or >25% marrow EBRT, 68Ga/225Ac allergy, CNS toxicity, ILD/pneumonitis, major CV/bleeding/uncontrolled disease, recent malignancy, prior trial, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests a GPC3-targeted theranostic pair in unresectable HCC. RYZ811: a Ga‑68–labeled GPC3-binding radiotracer (diagnostic radiopharmaceutical) for PET imaging to identify and select GPC3+ tumors and quantify target expression. RYZ801: an Ac‑225–labeled GPC3-binding radioligand therapy (alpha‑emitting radiopharmaceutical) that delivers short‑range, high‑LET alpha particles to GPC3+ cells, inducing DNA double‑strand breaks and cell death. Targeted cells/pathways: GPC3-expressing hepatocellular carcinoma cells, GPC3 is a heparan sulfate proteoglycan and Wnt/β‑catenin co‑receptor overexpressed in HCC.